MARKET

GNPX

GNPX

Genprex Inc
NASDAQ
0.5910
-0.0300
-4.83%
After Hours: 0.5840 -0.007 -1.18% 19:09 07/07 EDT
OPEN
0.6640
PREV CLOSE
0.6210
HIGH
0.6640
LOW
0.5701
VOLUME
155.50K
TURNOVER
--
52 WEEK HIGH
55.00
52 WEEK LOW
0.4229
MARKET CAP
6.46M
P/E (TTM)
-0.0372
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GNPX last week (0629-0703)?
Weekly Report · 1d ago
Weekly Report: what happened at GNPX last week (0622-0626)?
Weekly Report · 06/29 10:07
Genprex Secures Canadian Patent for Reqorsa Lung Cancer Therapy
TipRanks · 06/22 13:57
Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer
Benzinga · 06/22 13:09
Genprex says CIPO issues Notice of Allowance for patent
TipRanks · 06/22 13:09
Genprex wins Canadian patent allowance for Reqorsa combo with PD-1 or PD-L1 antibodies in lung cancer
PUBT · 06/22 13:02
Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
PR Newswire · 06/22 13:00
Weekly Report: what happened at GNPX last week (0615-0619)?
Weekly Report · 06/22 10:15
More
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells. Its oncology drug candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is developed in combination with approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). GPX-002 is being developed by the Company using the same construct for the treatment of both Type 1 diabetes and Type 2 diabetes. GPX-002 for Type 1 diabetes is designed to work by transforming alpha cells in the pancreas into functional beta-like cells.

Webull offers Genprex Inc stock information, including NASDAQ: GNPX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GNPX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GNPX stock methods without spending real money on the virtual paper trading platform.